You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
康希諾生物-B(06185.HK)預計年度由虧轉盈18.5億-20億元
格隆匯 01-28 19:11

格隆匯1月28日丨康希諾生物-B(06185.HK)公吿,經初步測算,預計截至2021年12月31日止年度集團實現收入為人民幣4,200.0百萬元到人民幣4,400.0百萬元,與截至2020年12月31日止年度約人民幣24.9百萬元相比,增加16,773.97%到17,577.49%。

預計截至2021年12月31日止年度實現歸屬於母公司所有者的淨利潤為人民幣1,850.0百萬元到人民幣2,000.0百萬元,而截至2020年12月31日止年度實現歸屬於母公司所有者的淨虧損約人民幣396.6百萬元,實現扭虧為盈。

預計截至2021年12月31日止年度實現歸屬於母公司所有者的扣除非經常性損益的淨利潤為人民幣1,740.0百萬元到人民幣1,880.0百萬元,而截至2020年12月31日止年度實現歸屬於母公司所有者的扣除非經常性損益的淨虧損約人民幣511.3百萬元,實現扭虧為盈。

本期業績變化的主要原因:報吿期內,本公司的重組新型冠狀病毒疫苗(5型腺病毒載體)(商品名:克威莎)已獲得國家藥品監督管理局批准於中國大陸附條件上市,並獲得海外多個國家的緊急使用授權,對本公司的收入及歸屬於母公司所有者的淨利潤產生積極影響;及主要為本期閒置資金現金管理收益增加。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account